Nutritional therapies for mental disorders

Nutrition Journal

Volumn 7, Issue 1, 2008, Pages

  Lakhan, Shaheen E ^a   Vieira, Karen F ^a  

^a Global Neuroscience Initiative Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; ASCORBIC ACID; CYANOCOBALAMIN; FLUOXETINE; FOLIC ACID; GLYCINE; ICOSAPENTAENOIC ACID; LITHIUM; LITHIUM CARBONATE; LITHIUM OROTATE; MAGNESIUM; MELATONIN; METHIONINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PAROXETINE; PHENYLALANINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; PYRIDOXINE; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; TAURINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; VITAMIN B GROUP; MINERAL; VITAMIN;

ASCORBIC ACID DEFICIENCY; BEDTIME DOSAGE; BIPOLAR DISORDER; CYANOCOBALAMIN DEFICIENCY; DIET SUPPLEMENTATION; FOLIC ACID DEFICIENCY; HIGH RISK PATIENT; HUMAN; HYPERICUM PERFORATUM; INCIDENCE; MAJOR DEPRESSION; MELATONIN DEFICIENCY; MENTAL DISEASE; NUTRIENT; NUTRITIONAL DEFICIENCY; OBSESSIVE COMPULSIVE DISORDER; OMEGA 3 DEFICIENCY; OMEGA 6 DEFICIENCY; PATIENT COMPLIANCE; PHENYLALANINE DEFICIENCY; PHOSPHATIDYLSERINE DEFICIENCY; PSYCHOTHERAPY; PYRIDOXINE DEFICIENCY; REVIEW; S ADENOSYL L METHIONINE DEFICIENCY; SCHIZOPHRENIA; SIDE EFFECT; SUICIDAL BEHAVIOR; TRYPTOPHAN DEFICIENCY; VITAMIN DEFICIENCY; DIET; DIET THERAPY; METHODOLOGY; STANDARD; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DIET; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; MENTAL DISORDERS; MINERALS; NUTRITION THERAPY; TREATMENT OUTCOME; VITAMINS;

EID: 39649095363     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-7-2     Document Type: Review

References (107)

1. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). RC Kessler WT Chiu O Demler EE Walters, Archives of General Psychiatry 2005 62 6 617 627 10.1001/archpsyc.62.6.617 15939839
2. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. K Demyttenaere R Bruffaerts J Posada-Villa I Gasquet V Kovess JP Lepine MC Angermeyer S Bernert G de Girolamo P Morosini G Polidori T Kikkawa N Kawakami Y Ono T Takeshima H Uda EG Karam JA Fayyad AN Karam ZN Mneimneh ME Medina-Mora G Borges C Lara R de Graaf J Ormel O Gureje Y Shen Y Huang M Zhang J Alonso JM Haro G Vilagut EJ Bromet S Gluzman C Webb RC Kessler KR Merikangas JC Anthony MR Von Korff PS Wang TS Brugha S Aguilar-Gaxiola S Lee S Heeringa BE Pennell AM Zaslavsky TB Ustun S Chatterji WHO World Mental Health Survey Consortium, JAMA 2004 291 21 2581 2590 10.1001/jama.291.21.2581 15173149
3. The Global Burden Of Disease. CJL Murray AD Lopez, World Health Organization 1996 270
4. Diagnostic and Statistical Manual of Mental Disorders. A American Psychiatric, Fourth edition, text revision Washington DC 2000
5. Management of lithium toxicity. WS Waring, Toxicol Rev 2006 25 4 221 230 10.2165/00139709-200625040-00003 17288494
6. Evolving trends in the long-term treatment of bipolar disorder. E Vieta AR Rosa, World J Biol Psychiatry 2007 8 1 4 11 10.1080/15622970601083280 17366344
7. Clinical nutrition: 3. The fuzzy boundary between nutrition and psycopharmacology. SN Young, CMAJ 2002 166 2 205 209 11826946
8. Nutrient imbalances in depressive disorders. Possible brain mechanisms. R Wurtman D O'Rourke JJ Wurtman, Ann N Y Acad Sci 1989 575 75 82 10.1111/j.1749-6632.1989.tb53234.x 2699207
9. Folate and depression-a neglected problem. SN Young, J Psychiatry Neurosci 2007 32 2 80 82 17353937
10. Fish consumption and major depression. JR Hibbeln, The Lancet 1998 351 9110 1213 10.1016/S0140-6736(05)79168-6
11. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. DO Rudin, Biol Psychiatry 1981 16 9 837 850 7028146
12. The dominant diseases of modernized societies as omega-3 essential fatty acid deficiency syndrome: substrate beriberi. DO Rudin, Med Hypotheses 1982 8 1 17 47 10.1016/0306-9877(82)90088-3 7062860
13. B complex vitamin patterns in geriatric and young adult inpatients with major depression. IR Bell JS Edman FD Morrow DW Marby S Mirages G Perrone HL Kayne JO Cole, J Am Geriatr Soc 1991 39 3 252 257 2005338
14. Rapid recovery from major depression using magnesium treatment. GA Eby KL Eby, Med Hypotheses 2006 67 2 362 370 10.1016/j.mehy.2006.01.047 16542786
15. The therapeutic predictability of tryptophan and tyrosine in the treatment of depression. R Buist, Int J Clin Nutr Rev 1983 3 1 3
16. A controlled clinical trial of L-tryptophan in acute mania. G Chouinard SN Young L Annable, Biol Psychiatry 1985 20 5 546 547 10.1016/0006-3223(85) 90026-5 3886024
17. Cultural symbolism of fish and the psychotropic properties of omega-3 fatty acids. LC Reis JR Hibbeln, Prostaglandins Leukot Essent Fatty Acids 2006 75 4-5 227 236 10.1016/j.plefa.2006.07.014 16962306
18. Fish consumption, depression, and suicidality in a general population. A Tanskanen JR Hibbeln J Hintikka K Haatainen K Honkalampi H Viinamaki, Arch Gen Psychiatry 2001 58 5 512 513 10.1001/archpsyc.58.5.512 11343534
19. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. C von Schacky, Vasc Health Risk Manag 2006 2 3 251 262 10.2147/vhrm.2006.2.3.251 17326331
20. Safety considerations of polyunsaturated fatty acids. J Eritsland, Am J Clin Nutr 2000 71 1 Suppl 197S 201S 10617971
21. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. AL Stoll WE Severus MP Freeman S Rueter HA Zboyan E Diamond KK Cress LB Marangell, Arch Gen Psychiatry 1999 56 5 407 412 10.1001/archpsyc.56.5.407 10232294
22. Depression. National Institute of Mental Health, National Institute of Mental Health, National Institutes of Health 2000 US Department of Health and Human Services, Bethesda (MD) [Reprinted September 2002].
23. The varied clinical presentations of major depressive disorder. AJ Rush, The Journal of clinical psychiatry 2007 68 8 Suppl 4 10 17640152
24. Neurobiology of serotonin in depression and suicide. CA Stockmeier, Ann N Y Acad Sci 1997 836 220 232 10.1111/j.1749-6632.1997.tb52362.x 9616801
25. Depression, suicide and the metabolism of serotonin in the brain. HM VanPraag, J Affect Disord 1982 4 4 275 290 10.1016/0165-0327(82)90025-8 6186712
26. The role of dopamine in mood disorders. DJ Diehl S Gershon, Compr Psychiatry 1992 33 2 115 120 10.1016/0010-440X(92)90007-D 1347497
27. Serotonin by stress interaction: a susceptibility factor for the development of depression? C Firk CR Markus, J Psychopharmacol 2007 17446201
28. The role of noradrenaline in depression: a review. BE Leonard, J Psychopharmacol 1997 11 4 Suppl S39 S47 9438232
29. GABA and mood disorders: a brief review and hypothesis. F Petty, J Affect Disord 1995 34 4 275 281 10.1016/0165-0327(95)00025-I 8550953
30. The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression. A McLean JS Rubinsztein TW Robbins BJ Sahakian, Psychopharmacology 2004 171 3 286 297 10.1007/s00213-003-1586-8 12955284
31. Effect of s-adenosyl-l-methionine (SAMe) upon depressive symptoms. A Agnoli V Andreoli M Casacchia R Cerbo, J Psychiatr Res 1976 13 1 43 54 10.1016/0022-3956(76)90008-X 787511
32. Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals. M aan het Rot DS Moskowitz G Pinard SN Young, J Psychiatry Neurosci 2006 31 4 253 262 16862243
33. L-tryptophan in depression. MJ Hoes, Journal of Orthomolecular Psychiatry 1982 4 231
34. Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders. HM Kravitz HC Sabelli J Fawcett, J Am Osteopath Assoc 1984 84 1 Suppl 119 123 6490415
35. The therapeutic potential for tryptophan and melatonin: possible roles in depression, sleep, Alzheimer's disease and abnormal aging. CP Maurizi, Med Hypotheses 1990 31 3 233 242 10.1016/0306-9877(90)90097-X 2345536
36. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. HG Ruhé NS Mason AH Schene, Mol Psychiatry 2007 12 4 331 359 10.1038/sj.mp.4001949 17389902
37. S-adenosylmethionine as an antidepressant: A double blind trial versus placebo. D DeLeo, Curr Ther Res 1987 41 6 865 870
38. S-adenosylmethionine in depression. A literature review and preliminary report. PG Janicak J Lipinski JM Davis JE Comaty C Waternaux B Cohen E Altman RP Sharma, Ala J Med Sci 1988 25 3 306 313 3052139
39. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. PB Adams S Lawson A Sanigorski AJ Sinclair, Lipids 1996 31 Suppl S157 S161 10.1007/BF02637069 8729112
40. Hypervitaminosis A following long-term use of high-dose fish oil supplements. BP Grubb, Chest 1990 97 5 1260 10.1378/chest.97.5.1260 2331929
41. Creativity and mental illness. Z Rihmer X Gonda A Rihmer, Psychiatr Hung 2006 21 4 288 294 17170470
42. Manic depression-a disorder of central dopaminergic rhythm. GM Skutsch, Med Hypotheses 1981 7 6 737 746 10.1016/0306-9877(81)90085-2 7278735
43. Manic depression: a multiple hormone disorder? GM Skutsch, Biol Psychiatry 1985 20 6 662 668 10.1016/0006-3223(85)90101-5 3888297
44. Vanadium and manic depressive psychosis. GJ Naylor, Nutr Health 1984 3 79 85 6443582
45. Vanadium: a possible aetiological factor in manic depressive illness. GJ Naylor AH Smith, Psychol Med 1981 11 249 256 6791192
46. Folate, vitamin B12, and neuropsychiatric disorders. T Botiglieri, Nutr Rev 1996 54 382 390 9155210
47. Reduced red-cell folate in mania. CI Hasanah UA Khan M Musalmah SM Razali, J Affect Disord 1997 46 95 99 10.1016/S0165-0327(97)00096-7 9479613
48. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. Y Osher Y Bersudsky RH Belmaker, 2005 66 726 729 15960565
49. The clinical applications of lithium orotate. A two years study. HA Nieper, Agressologie 1973 14 6 407 411 4607169
50. Lithium orotate in the treatment of alcoholism and related conditions. HE Sartori, Alcohol 1986 3 2 97 100 10.1016/0741-8329(86)90018-2 3718672
51. Effects of chronic lithium and sodium valproate on concentrations of brain amino acids. T O'Donnell S Rotzinger M Ulrich CC Hanstock TT Nakashima PH Silverstone, Eur Neuropsychopharmacol 2003 13 4 220 227 10.1016/S0924-977X(03) 00070-1 12888180
52. The incidence of operationally defined schizophrenia in Camberwell 1965-84. E Castle S Wessely G Der RM Murray, British Journal of Psychiatry 1991 159 790 794 1790446
53. Amino acids in schizophrenia: evidence for lower tryptophan availability during treatment with atypical antipsychotics? DFFMMA van der Heijden S Tuinier AES Sijben RS Kahn WMA Verhoeven, Journal of Neural Transmission 2005 112 4 577 585 10.1007/s00702-004-0200-5 15372327
54. Amelioration of negative symptoms in schizophrenia by glycine. DC Javitt I Zylberman SR Zukin U Heresco-Levy JP Lindenmayer, Am J Psychiatry 1994 151 8 1234 1236 8037263
55. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. E Leiderman I Zylberman SR Zukin TB Cooper DC Javitt, Biol Psychiatry 1996 39 3 213 215 10.1016/0006-3223(95)00585-4 8837983
56. Adjunctive high-dose glycine in the treatment of schizophrenia. DC Javitt G Silipo A Cienfuegos AM Shelley N Bark M Park JP Lindenmayer R Suckow SR Zukin, Int J Neuropsychopharmacol 2001 4 4 385 391 11806864
57. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis. M Peet, British Journal of Psychiatry 2004 184 404 408 10.1192/bjp.184.5.404 15123503
58. Fat consumption and schizophrenia. O Christensen E Christensen, Acta Psychiatr Scand 1988 78 5 587 591 10.1111/j.1600-0447.1988.tb06388.x 3232536
59. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. M Peet, Prostaglandins Leukot Essent Fatty Acids 2003 69 6 477 485 10.1016/j.plefa.2003. 08.020 14623502
60. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. R Emsley C Myburgh P Oosthuizen SJ van Rensburg, Am J Psychiatry 2002 159 9 1596 1598 10.1176/appi.ajp.159.9.1596 12202284
61. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. BK Puri AJ Richardson DF Horrobin T Easton N Saeed A Oatridge JV Hajnal GM Bydder, Int J Clin Pract 2000 54 1 57 63 10750263
62. Laterality changes accompanying symptom remission in schizophrenia following treatment with eicosapentaenoic acid. AJ Richardson T Easton JH Gruzelier BK Puri, Int J Psychophysiol 1999 34 3 333 339 10.1016/S0167-8760(99) 00090-2 10610057
63. Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. AJ Richardson T Easton BK Puri, Eur Neuropsychopharmacol 2000 10 3 189 193 10.1016/S0924- 977X(00)00068-7 10793321
64. The role of omega 3 fatty acids in behaviour, cognition and mood. AJ Richardson, Scandinavian Journal of Nutrition 2003 47 2 92 98 10.1080/11026480310007944
65. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. JK Yao S Magan AF Sonel JA Gurklis R Sanders RD Reddy, Prostaglandins Leukot Essent Fatty Acids 2004 71 3 171 176 10.1016/j.plefa.2004.03.011 15253886
66. Quick Reference to the Diagnostic Criteria from DSM-IV-TR. A American Psychiatric, Arlington, VA 2000
67. An update on the pharmacological treatment of obsessive-compulsive disorder. LF Fontenelle AL Nascimento MV Mendlowicz RG Shavitt M Versiani, Expert Opin Pharmacother 2007 8 5 563 583 10.1517/14656566.8.5.563 17376013
68. L-tryptophan in obsessive-compulsive disorders. JA Yaryura-Tobias HN Bhagavan, Am J Psychiatry 1977 134 11 1298 1299 333953
69. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. A Szegedi R Kohnen A Dienel M Kieser, British Medical Journal 2005 330 7494 759 15802718
70. A double-blind, randomized trial of St. John's wort, fluoxetine, and placebo in major depressive disorder. M Fava J Alpert AA Nierenberg D Mischoulon MW Otto J Zajecka H Murck JF Rosenbaum, J Clin Psychopharmacol 2005 25 5 441 447 10.1097/01.jcp.0000178416.60426.29 16160619
71. Vitamin B12 and folate status in acute geropsychiatric inpatients: affective and cognitive characteristics of a vitamin nondeficient population. IR Bell JS Edman DW Marby A Satlin T Dreier B Liptzin JO Cole, Biol Psychiatr 1990 27 2 125 137 10.1016/0006-3223(90)90642-F
72. The pharmacokinetics of oral L-tryptophan: effects of dose and concomitant pyridoxine, allopurinol or nicotinamide administration. AR Green JK Aronson, Adv Biol Psychiatr 1983 10 67 81
73. Lecithin in the treatment of mania: double-blind, placebo-controlled trials. BM Cohen JF Lipinski RI Altesman, Am J Psychiatr 1982 139 1162 1164 7051871
74. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: A prospective open-label trial. J Wozniak J Biederman E Mick J Waxmonsky L Hantsoo C Best JE Cluette-Brown M Laposata, Eur Neuropsychopharmacol 2007 17 6-7 440 447 10.1016/j.euroneuro.2006.11.006 17258897
75. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomized double-blind placebo-controlled study. S Frangou M Lewis P McCrone, Br J Psychiatry 2006 188 46 50 10.1192/bjp.188.1.46 16388069
76. Food antibodies in acute psychoses. K Rix J Ditchfield DL Freed DP Goldberg VF Hillier, Psychol Med 1985 15 2 347 354 4023138
77. Nutritional Medicine. S Davies A Stewart, London, Pan Books 1987 403
78. Course of seasonal bipolar disorder influenced by caffeine. L Tondo N Rudas, J Affective Disorder 1991 22 249 251 10.1016/0165-0327(91)90071-Y
79. Dietary interferences with lithium therapy. P Castrogiovanni F Pieraccini, Eur Psychiatr 1996 11 53 54 10.1016/0924-9338(96)80461-5
80. Vitamin B6 in clinical neurology. AL Bernstein, Annal NY Acad Sci 1990 585 250 260 10.1111/j.1749-6632.1990.tb28058.x
81. Vitamin B12 hypovitaminosis in mental diseases. E Edwin K Holten FR Norum A Schrumpf OE Skaug, Acta Med Scand 1965 177 689 699 14334662
82. Do vitamins or minerals (apart from lithium) have mood-stabilizing effects? CW Popper, J Clin Psychiatry 2001 62 12 933 944 11780872
83. Serum B12 and folate concentrations in mental patients. T Haellstroem, Acta Psychiatr Scand 1969 45 1 19 36 10.1111/j.1600-0447.1969.tb06198.x 5345562
84. Vitamin C concentrations in patients in a psychiatric hospital. CJ Schorah DB Morgan RP Hullin, Hum Nutr Clin Nutr 1983 37C 447 452
85. Ascorbic acid in chronic psychiatric patients: a controlled trial. G Milner, Br J Psychiatr 1963 109 294 299
86. Plasma vitamin C in the prevention and treatment of autism. B Rimland, Autism Res Rev Intl 1998 12 2 3
87. Folate and long-chain polyunsaturated fatty acids in psychiatric disease. FAJ Muskiet RFJ Kemperman, J Nutr Biochem 2006 17 11 717 727 10.1016/j.jnutbio.2006.02.001 16650750
88. Folic acid as ultimate in disease prevention: Folate also improves mental health. MJ Taylor J Geddes, BMJ 2004 328 7442 768 769 15044304 10.1136/bmj.328.7442.768-c
89. Lecithin in mania: a preliminary report. BM Cohen AL Miller JF Lipinski HG Pope, Am J Psychiatr 1980 137 242 243 6101528
90. Omega-3 fatty acids and mood disorders. G Parker NA Gibson H Brotchie G Heruc AM Rees D Hadzi-Pavlovic, Am J Psychiatry 2006 163 6 969 978 10.1176/appi.ajp.163.6.969 16741195
91. Is low dietary intake of omega-3 fatty acids associated with depression? R Hakkarainen T Partonen J Haukka J Virtamo D Albanes J Lönnqvist, Am J Psychiatry 2004 161 3 567 569 10.1176/appi.ajp.161.3.567 14992986
92. Depression linked to lower omega-3 fatty acid levels. International medical news group, Family Practice news 2004 34 8 54(51)
93. The electrophysiologic basis for the antiarrhythmic and anticonvulsant effects of n-3 polyunsaturated fatty acids: heart and brain. A Leaf, Lipids 2001 36 Suppl S107 110 10.1007/s11745-001-0691-y 11837982
94. Linoleic acid in the treatment of lithium toxicity and familial tremor. J Lieb, Prostaglandins Med 1980 4 275 279 10.1016/0161-4630(80)90022-1 7394066
95. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. HC Sabelli J Fawcett F Gusovsky JL Javaid P Wynn J Edwards H Jeffriess H Kravitz, J Clin Psychiatry 1986 47 2 66 70 3944066
96. L-phenylalanine. M Simonson, J Clin Psychiatry 1985 46 8 355 4019429
97. Association between the tryptophan hydroxylase gene and manic-depressive illness. F Bellivier M Leboyer P Courtet C Buresi B Beaufils D Samolyk JF Allilaire J Feindgold J Mallet A Malafosse, Arch Gen Psychiatr 1998 55 33 37 10.1001/archpsyc.55.1.33 9435758
98. Tryptophan depletion in recently manic patients treated with lithium. F Cassidy E Murry BJ Carroll, Biol Psychiatr 1998 43 230 232 10.1016/S0006- 3223(97)00010-3
99. Tryptophan depletion in stable lithium-treated patients with bipolar disorder in remission. C Benkelfat B Seletti RM Palmour J Hillel M Ellenbogen SN Young, Arch Gen Psychiatry 1995 52 154 155 7848051
100. L-tryptophan in neuropsychiatric disorders: a review. R Sandyk, Intl J Neurosci 1992 67 127 144
101. The switch mechanism and the bipolar/unipolar dichotomy. MWP Carney TK Chary T Bottiqlieri EH Reynolds, Br J Psychiatr 1989 154 48 51
102. Clinical correlations of one-carbon metabolism abnormalities. LC Tolbert A Monti W Walter-Ryan RD Alacron B Bahar JT Keriotis JG Allison A Cates F Antun JR Smythies, Prog Neuropsychopharmacol Biol Psychiatr 1988 12 4 491 502 10.1016/0278-5846(88)90108-X
103. Switch and S-adenosylmethionine. MWP Carney TK Chavy T Bottiglieri LH Reynolds, Ala J Med Sci 1988 25 3 316 319 3052141
104. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. C Pacchierotti S Iapichino L Bossini F Pieraccini P Castrogiovanni, Front Neuroendocrinol 2001 22 18 32 10.1006/frne.2000.0202 11141317
105. Melatonin suppression by light in euthymic bipolar and unipolar patients. JI Nurnberger S Adkins DK Lahiri A Mayeda K Hu A Lewy A Miller ES Bowman MJ Miller L Rau C Smiley D Davis-Singh, Arch Gen Psychiatry 2000 57 572 579 10.1001/archpsyc.57.6.572 10839335
106. Guidelines for prescribing melatonin. D Avery M Lenz C Landis, Ann Med 1998 30 122 130 9556099
107. Abnormal plasma levels of serine, methionine and taurine in transient, acute, polymorphic psychosis. D Fekkes L Pepplinkhuizen R Verheij J Bruinvels, Psychiatry Res 1994 51 11 18 10.1016/0165-1781(94)90043-4 8197268